广州，2024年4月14日 —— 在近日举行的“2024大湾区肝病国际论坛暨消除病毒性肝炎大会”上，肝病专家们聚集一堂，共同探讨了病毒性肝炎的防控策略和治疗前景。本次大会于12日至14日在广州盛大召开，吸引了众多医疗专业人士的关注。
会议期间，专家们强调，消除病毒性肝炎这一全球公共卫生问题需要从预防、诊断、治疗和社区干预等多个层面进行综合推进。特别是对于乙肝，尽管现有的药物疗法已经显著改善了患者的生活质量，但实现乙肝表面抗原转阴，即临床意义上的“治愈”，仍然面临挑战。
南[未提供专家全名]指出，乙肝治愈是全球医学界共同追求的理想，然而，当前的药物手段尚不足以实现这一目标。他呼吁，医学界应加大新药研发力度，以期在不久的将来攻克这一难题。“乙肝治愈的突破，将依赖于创新药物的问世。”他强调。
本次论坛为国内外肝病专家提供了交流平台，共同探讨了病毒性肝炎的最新科研成果和临床实践，旨在推动全球肝病防治工作的进步，尤其是在新药研发领域的合作与创新。与会者一致认为，通过全球医学界的共同努力，乙肝治愈的愿景有望早日变为现实。
英语如下：
**News Title:** “Experts Agree: Long Road to Curing Hepatitis B, New Drug Development Key – Guangdong Bay Area Liver Disease Forum Focuses on Viral Hepatitis Elimination”
**Keywords:** Liver Disease Forum, Curing Hepatitis B, New Drug Development
**News Content:**
**2024 Greater Bay Area Liver Disease International Forum: Experts Call for Enhanced New Drug Development to Achieve Hepatitis B Cure Goal**
Guangzhou, April 14, 2024 – At the recently concluded “2024 Greater Bay Area Liver Disease International Forum and Viral Hepatitis Elimination Congress,” liver disease experts convened to discuss strategies and treatment prospects for combating viral hepatitis. The conference, held from April 12 to 14 in Guangzhou, drew significant attention from medical professionals.
During the event, experts underscored the need for a comprehensive approach in addressing the global public health issue of viral hepatitis, encompassing prevention, diagnosis, treatment, and community intervention. Specifically, for hepatitis B, while current drug therapies have notably improved patients’ quality of life, achieving seroconversion of hepatitis B surface antigen (HBsAg) negativity, or a “cure” in clinical terms, remains challenging.
Dr. Nan [专家未提供全名] pointed out that a cure for hepatitis B is a shared aspiration in the global medical community. However, he noted that current therapeutic options are insufficient to attain this goal. He called for increased efforts in new drug development to overcome this challenge in the near future. “A breakthrough in hepatitis B cure will rely on the advent of innovative medications,” he emphasized.
The forum served as a platform for domestic and international liver disease experts to exchange insights on the latest research findings and clinical practices in viral hepatitis, aiming to advance global efforts in liver disease prevention and control, particularly in collaboration and innovation in new drug development. Attendees一致 agreed that with the collective endeavor of the global medical community, the vision of a hepatitis B cure could become a reality sooner rather than later.
【来源】http://www.chinanews.com/sh/2024/04-14/10198660.shtml
Views: 1